CYP2B6*6 is associated with increased breast cancer risk

Justenhoven C, Pentimalli D, Rabstein S, Harth V, Lotz A, Pesch B, Bruening T, Doerk T, Schuermann P, Bogdanova N, Park-Simon TW, Couch FJ, Olson JE, Fasching P, Beckmann M, Häberle L, Ekici A, Hall P, Czene K, Liu J, Li J, Baisch C, Hamann U, Ko YD, Brauch H (2014)

Publication Type: Journal article

Publication year: 2014

Journal

International Journal of Cancer Wiley-Blackwell

Publisher: Wiley-Blackwell

Book Volume: 134

Pages Range: 426-30

Journal Issue: 2

DOI: 10.1002/ijc.28356

Abstract

The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. The GENICA breast cancer case-control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde

Involved external institutions

Karolinska Institute SE Sweden (SE) Eberhard Karls Universität Tübingen DE Germany (DE) Institut für Prävention und Arbeitsmedizin der Deutschen Gesetzlichen Unfallversicherung (IPA) DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Genome Institute of Singapore SG Singapore (SG) Deutsches Krebsforschungszentrum (DKFZ) DE Germany (DE) Mayo Clinic US United States (USA) (US)

How to cite

APA:

Justenhoven, C., Pentimalli, D., Rabstein, S., Harth, V., Lotz, A., Pesch, B.,... Brauch, H. (2014). CYP2B6*6 is associated with increased breast cancer risk. International Journal of Cancer, 134(2), 426-30. https://doi.org/10.1002/ijc.28356

MLA:

Justenhoven, Christina, et al. "CYP2B6*6 is associated with increased breast cancer risk." International Journal of Cancer 134.2 (2014): 426-30.

BibTeX: Download